CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease

被引:13
|
作者
Burnight, Erin R. [1 ,2 ]
Bohrer, Laura R. [1 ,2 ]
Giacalone, Joseph C. [1 ,2 ]
Klaahsen, Darcey L. [1 ,2 ]
Daggett, Heather T. [1 ,2 ]
East, Jade S. [1 ,2 ]
Madumba, Robert A. [1 ,2 ]
Worthington, Kristan S. [1 ,3 ]
Mullins, Robert F. [1 ,2 ]
Stone, Edwin M. [1 ,2 ]
Tucker, Budd A. [1 ,2 ]
Wiley, Luke A. [1 ,2 ]
机构
[1] Univ Iowa, Carver Coll Med, Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA
[2] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, 375 Newton Rd, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA
来源
CRISPR JOURNAL | 2018年 / 1卷 / 01期
基金
美国国家卫生研究院;
关键词
NEURONAL CEROID-LIPOFUSCINOSIS; MOUSE MODEL; IN-VITRO; MUTATIONS; DESIGN; SEQ;
D O I
10.1089/crispr.2017.0015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a rare progressive neurodegenerative disorder caused by mutations in CLN3. Patients present with early-onset retinal degeneration, followed by epilepsy, progressive motor deficits, cognitive decline, and premature death. Approximately 85% of individuals with Batten disease harbor at least one allele containing a 1.02 kb genomic deletion spanning exons 7 and 8. This study demonstrates CRISPR-Cas9-based homology-dependent repair of this mutation in induced pluripotent stem cells generated from two independent patients: one homozygous and one compound heterozygous for the 1.02 kb deletion. Our strategy included delivery of a construct that carried >3 kb of DNA: wild-type CLN3 sequence and a LoxP-flanked, puromycin resistance cassette for positive selection. This strategy resulted in correction at the genomic DNA and mRNA levels in the two independent patient lines. These CRISPR-corrected isogenic cell lines will be a valuable tool for disease modeling and autologous retinal cell replacement.
引用
收藏
页码:75 / 87
页数:13
相关论文
共 10 条
  • [1] Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells
    Wu, Yuxuan
    Zhou, Hai
    Fan, Xiaoying
    Zhang, Ying
    Zhang, Man
    Wang, Yinghua
    Xie, Zhenfei
    Bai, Meizhu
    Yin, Qi
    Liang, Dan
    Tang, Wei
    Liao, Jiaoyang
    Zhou, Chikai
    Liu, Wujuan
    Zhu, Ping
    Guo, Hongshan
    Pan, Hong
    Wu, Chunlian
    Shi, Huijuan
    Wu, Ligang
    Tang, Fuchou
    Li, Jinsong
    CELL RESEARCH, 2015, 25 (01) : 67 - 79
  • [2] Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells
    Xu, Xiaohong
    Tay, Yilin
    Sim, Bernice
    Yoon, Su-In
    Huang, Yihui
    Ooi, Jolene
    Utami, Kagistia Hana
    Ziaei, Amin
    Ng, Bryan
    Radulescu, Carola
    Low, Donovan
    Ng, Alvin Yu Jin
    Loh, Marie
    Venkatesh, Byrappa
    Ginhoux, Florent
    Augustine, George J.
    Pouladi, Mahmoud A.
    STEM CELL REPORTS, 2017, 8 (03): : 619 - 633
  • [3] CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells
    Xie Yingjun
    Xie Yuhuan
    Chen Yuchang
    Li Dongzhi
    Wang Ding
    Song Bin
    Yang Yi
    Lu Dian
    Xue Yanting
    Xiong Zeyu
    Liu Nengqing
    Chen Diyu
    Sun Xiaofang
    ANNALS OF HEMATOLOGY, 2019, 98 (12) : 2661 - 2671
  • [4] Efficient and Precise CRISPR/Cas9-Mediated MECP2 Modifications in Human-Induced Pluripotent Stem Cells
    Thi Thanh Huong Le
    Ngoc Tung Tran
    Thi Mai Lan Dao
    Dinh Dung Nguyen
    Huy Duong Do
    Thi Lien Ha
    Kuhn, Ralf
    Thanh Liem Nguyen
    Rajewsky, Klaus
    Van Trung Chu
    FRONTIERS IN GENETICS, 2019, 10
  • [5] Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system
    Lyu, Cuicui
    Shen, Jun
    Wang, Rui
    Gu, Haihui
    Zhang, Jianping
    Xue, Feng
    Liu, Xiaofan
    Liu, Wei
    Fu, Rongfeng
    Zhang, Liyan
    Li, Huiyuan
    Zhang, Xiaobing
    Cheng, Tao
    Yang, Renchi
    Zhang, Lei
    STEM CELL RESEARCH & THERAPY, 2018, 9
  • [6] Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery
    De Masi, Claudia
    Spitalieri, Paola
    Murdocca, Michela
    Novelli, Giuseppe
    Sangiuolo, Federica
    HUMAN GENOMICS, 2020, 14 (01)
  • [7] Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9
    Park, Chul-Yong
    Sung, Jin Jea
    Cho, Sung-Rae
    Kim, Jongwan
    Kim, Dong-Wook
    STEM CELL REPORTS, 2019, 12 (06): : 1242 - 1249
  • [8] CRISPR/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells o severe congenital neutropenia patients
    Nasri, Masoud
    Ritter, Malte
    Mir, Perihan
    Dannenmann, Benjamin
    Aghaallaei, Narges
    Amend, Diana
    Makaryan, Vahagn
    Xu, Yun
    Fletcher, Breanna
    Bernhard, Regine
    Steiert, Ingeborg
    Haehnel, Karin
    Berger, Juergen
    Koch, Iris
    Sailer, Brigitte
    Hipp, Katharina
    Zeidler, Cornelia
    Klimiankou, Maksim
    Bajoghli, Baubak
    Dale, David C.
    Welte, Karl
    Skokowa, Julia
    HAEMATOLOGICA, 2020, 105 (03) : 598 - 609
  • [9] CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients
    Provenzano, Claudia
    Cappella, Marisa
    Valaperta, Rea
    Cardani, Rosanna
    Meola, Giovanni
    Martelli, Fabio
    Cardinali, Beatrice
    Falcone, Germana
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 9 : 337 - 348
  • [10] Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection
    Caron, Jerome
    Pene, Veronique
    Tolosa, Laia
    Villaret, Maxime
    Luce, Eleanor
    Fourrier, Angelique
    Heslan, Jean-Marie
    Saheb, Samir
    Bruckert, Eric
    Jose Gomez-Lechon, Maria
    Tuan Huy Nguyen
    Rosenberg, Arielle R.
    Weber, Anne
    Dubart-Kupperschmitt, Anne
    STEM CELL RESEARCH & THERAPY, 2019, 10 (1)